QLT Ophthalmics, Inc., a wholly-owned U.S. subsidiary of QLT Inc. has selected Veeva System's multi-tenant SaaS (News - Alert) CRM system built on the cloud computing model.
QOI was formed by QLT Inc. in Q4 2009 to take over the sales and marketing of Visudyne in the U.S. from Novartis Pharma AG.
Veeva CRM proved the only system flexible and scalable enough to meet QOI's rapidly growing needs, according to QOI's Director of Commercial Operations, Scott Jones.
'Veeva CRM is easily scalable, which was very important to us as we hope to scale-up our commercial operations as we bring new therapeutics to the market,' said Jones, in a statement.
Jones said that the Veeva CRM system is also as flexible in its pricing model as it is technologically.
"We didn't have to make a huge investment in Veeva up-front but when we are ready for more 'system' with additional functionality and seat licenses, we can pay incrementally to build on and not have wasted any money with our initial outlay,' he said.
Officials with Veeva said that the ophthalmic pharmaceutical company went live with the complete Veeva CRM suite in February.
Company officials said that a multi-tenant SaaS application built on the cloud computing model, Veeva CRM requires no hardware or software to purchase, scale, or maintain.
Customers also benefit from free, automatic upgrades every 90 days so users will always be working on the latest version of the software with the very latest compliance changes and system enhancements.
'We looked at most of the Pharma CRM vendors, but knew fairly quickly that Veeva was the best fit for us. The fact that they were able to implement the system in less than 6 weeks was the final feather in their cap,' said Jones.
Veeva Systems is a major player in multi-tenant SaaS-based solutions for the global life sciences industry.
Anil Sharma is a contributing editor for TMCnet. To read more of Anil's articles, please visit his columnist page.Edited by Juliana Kenny